Immix Biopharma (NASDAQ:IMMX - Get Free Report) was upgraded by investment analysts at Wall Street Zen to a "hold" rating in a report issued on Friday.
Separately, HC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Immix Biopharma in a research note on Wednesday, June 4th.
View Our Latest Stock Report on IMMX
Immix Biopharma Price Performance
Immix Biopharma stock traded down $0.10 during midday trading on Friday, reaching $2.07. 121,451 shares of the stock traded hands, compared to its average volume of 153,846. The stock's fifty day moving average is $2.14 and its 200-day moving average is $1.97. Immix Biopharma has a 12 month low of $1.26 and a 12 month high of $3.00.
Institutional Investors Weigh In On Immix Biopharma
A hedge fund recently bought a new stake in Immix Biopharma stock. Jane Street Group LLC purchased a new position in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 17,523 shares of the company's stock, valued at approximately $39,000. Jane Street Group LLC owned 0.06% of Immix Biopharma as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 11.26% of the company's stock.
About Immix Biopharma
(
Get Free Report)
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Further Reading
Before you consider Immix Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immix Biopharma wasn't on the list.
While Immix Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
